Haemonetics (HAE) Peer Comparison

$104.10

$-0.91 (-0.86%)

As on 28-Aug-2026 13:42EDT

Market cap

$4,924 Mln

Revenue (TTM)

$1,352 Mln

P/E Ratio

52.3

P/B Ratio

5.9

Div. Yield

0 %

Edit

	Haemonetics (HAE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	4,924	12,753	10,906	10,222	9,762
Revenue ($ Mln)	1,352	1,505	613	785	2,589
Net Profit ($ Mln)	96.29	160.59	-188.05	41.54	222.40
Net Margin (%)	7.12	10.67	-30.68	5.29	8.59
RoE (%)	11.01	10.86	-28.10	1.97	3.04
Price to Earnings	52.28	79.35	--	251.57	44.47
Price-To-Book	5.89	8.41	16.38	4.84	1.26

Income Statement ($ Mln)

	Haemonetics (HAE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	1,334.03	1,403.67	507.44	738.26	2,583.20
Cost of Revenue	590.44	461.23	114.23	390.63	1,239.60
Gross Profit	743.59	942.44	393.22	347.62	1,343.60
Operating Expenses	502.19	753.19	479.95	288.05	1,077.50
Operating Profit (EBIT)	241.40	189.25	-86.73	59.58	270.50
Other Income	--	--	--	--	--
Profit before Tax	128.03	205.13	-193.04	62.38	995.50
Provision for Tax	30.72	27.44	-5.35	13.49	235.60
Profit after Tax (Net Income)	97.31	177.69	-187.69	48.89	759.90
Minority Interest	--	--	--	--	--
Consolidated Profit	167.68	177.69	--	--	--

	Haemonetics (HAE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	796.32	1,427.60	656.16	2,106.13	7,453.60
Minority Interest	--	--	--	--	--
Non-Current Liabilities	1,317.01	215.78	136.06	707.74	2,605.90
Current Liabilities	282.60	183.13	101.28	135.83	517.00
Total Liabilities	2,395.93	1,826.52	893.49	2,949.70	10,576.50

	Haemonetics (HAE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	1,561.05	609.84	418.50	1,812.31	7,670.30
Current Assets	834.88	1,216.68	474.98	1,137.39	2,906.20
Total Assets	2,395.93	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	1,224.58	219.70	139.64	689.95	1,531.00
Net Current Assets	552.28	1,033.55	373.71	1,001.56	2,389.20

	Haemonetics (HAE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	293.22	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-179.55	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	-178.46	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

	Haemonetics (HAE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	4.79	11.76	-22.53	1.79	8.98
ROE (%)	12.03	13.78	-26.38	2.40	10.84
ROA (%)	4.02	10.58	-20.09	1.69	7.62
EBIT Margin (%)	--	--	--	--	--
Net Margin (%)	7.29	12.66	-36.99	6.62	29.42
Cash Profit Margin (%)	--	--	--	--	--

	Haemonetics (HAE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	-0.02	0.17	0.32	0.16	0.01
EBIT Growth (%)	--	--	--	--	--
Net Profit Growth (%)	-41.97	1,168.11	-28.23	291.64	141.20
EPS Growth (%)	-0.38	11.64	-0.24	2.90	1.43
Book Value Growth (%)	--	--	--	--	--

	Haemonetics (HAE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	26.77	68.93	-34.59	189.42	--
Price / Book Value	3.27	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	11.47	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

	Haemonetics (HAE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	1.54	0.15	0.21	0.33	0.21
Short term debt to equity ratio	0.01	0.01	--	0.01	0.01
Current Ratio	2.95	6.64	4.69	8.37	5.62
Quick Ratio	1.87	4.29	4.06	7.12	4.19
Interest Coverage	5.46	157.46	-40.65	3.69	21.32

	Haemonetics (HAE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	16.26	13.54	21.40	21.48	18.29
Asset Turnover	0.55	0.84	0.54	0.26	0.26
Receivable days	57.43	46.54	60.95	72.41	65.39
Inventory Days	207.70	331.92	193.84	146.53	221.09
Payable days	36.51	26.16	60.19	29.05	37.02
Cash Conversion Cycle	228.62	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.